Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:31:34.848Z.
Calculation as of: 2026-10-06T15:31:34.848Z.
Quote observation: 2026-10-06T15:28:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8c4723d74b6f0443862f85907ca9030ea6941843cb736177163438a313e1ca1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$142.15M
EV/EBITDA Ratio
455.98x
TTM Avg
352.35x
3Y Avg
117.66x
5Y Avg
91.76x
Market Cap
$136.88M
EV/EBITDA Ratio
N/A
TTM Avg
693.21x
3Y Avg
347.06x
5Y Avg
258.50x
Market Cap
$146.58M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Cognition Inc (ACOG) | $140.02M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | N/A | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $142.15M | 455.98x | 352.35x | 117.66x | 91.76x |
| Nyxoah S.A. (NYXH)vs › | $143.60M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.88M | N/A | 693.21x | 347.06x | 258.50x |
| Freenome, Inc. (FRNM)vs › | $135.70M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $135.17M | N/A | 53.44x | 53.44x | 53.44x |
| Immuneering Corporation (IMRX)vs › | $146.12M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | N/A | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
